Background
Methods
Materials and study design
Adjudicated final diagnosis
Determination of circulating miR-1
Investigational cTnI measurements
Follow-up and clinical end-points
Statistical analysis
Results
Characteristics of patients
Group | AMI | non-AMI | non-ACP | χ2/ F / Z value | P value | P1 value | P2 value | P3 value |
---|---|---|---|---|---|---|---|---|
(n = 174) | (n = 167) | (n = 100) | ||||||
Age(years) | 68 (55, 75) | 67 (60, 75) | 56 (45, 69) | 26.894 | 0.000 | 0.252 | 0.000 | 0.000 |
Male gender | 121 (69.54) | 121 (72.46) | 75 (75) | 1.536 | 0.464 | 0.460 | 0.226 | 0.566 |
Current smokers | 116 (66.67) | 47 (28.14) | 8 (8) | 126.207 | 0.000 | 0.000 | 0.000 | 0.000 |
Hypertension | 127 (72.99) | 119 (71.26) | 30 (30) | 85.888 | 0.000 | 0.999 | 0.000 | 0.000 |
Diabetes mellitus | 53 (30.46) | 45 (26.95) | 6 (6) | 32.261 | 0.000 | 0.259 | 0.000 | 0.000 |
Hypercholesterolemia | 14 (8.05) | 15 (8.98) | 3 (3) | 5.585 | 0.061 | 0.382 | 0.079 | 0.018 |
Hypertriglyceridemia | 36 (20.69) | 31 (18.56) | 10 (10) | 9.999 | 0.007 | 0.043 | 0.003 | 0.187 |
History of CVD | 7 (4.02) | 7 (4.19) | 5 (5) | 0.139 | 0.933 | 0.890 | 0.710 | 0.804 |
Heart rate(bpm) | 88.5 (73, 107) | 72 (64, 81) | 72 (61, 81) | 97.883 | 0.000 | 0.000 | 0.000 | 0.776 |
Body mass index(kg/m2) | 24.15 (21.51, 27.41) | 23.62 (20.43, 26.03) | 23.1 (20.46, 25.78) | 6.861 | 0.032 | 0.024 | 0.032 | 0.773 |
Creatinine(μmol/l) | 88.4 (70.65, 109.25) | 70.9 (65.2, 89.3) | 71 (63.7, 85.3) | 38.343 | 0.000 | 0.000 | 0.000 | 0.298 |
GFR (mL/min/1.73 m2) | 71.46 (52.68, 90.3) | 87.3 (73.37, 96.21) | 93.54 (76.26, 105.61) | 45.125 | 0.000 | 0.000 | 0.000 | 0.002 |
Creatine kinase MB(U/L) | 33 (14.5, 104.2) | 15.5 (12.3, 19.5) | 8.9 (8.3, 9.45) | 185.337 | 0.000 | 0.000 | 0.000 | 0.000 |
cTnI(μg/L) | 3.23 (0.62, 16.62) | 0.05 (0.00, 0.34) | 0.00 (0.00, 0.00) | 233.657 | 0.000 | 0.000 | 0.000 | 0.000 |
The relative expression of miR-1 was different in each group
Reperfusion therapy affected miR-1
Diagnostic value of miR-1 in patients with ACP
Biomarker | AUC (95%CI) | P value | Sen. | Spe. | PPV | NPV | LR+ | LR- |
---|---|---|---|---|---|---|---|---|
miR-1 | 0.863 (0.820~0.906) | 0.000 | 87.9 | 80.2 | 0.823 | 0.865 | 4.450 | 0.150 |
cTnI | 0.864 (0.823~0.906) | 0.000 | 79.3 | 91.6 | 0.908 | 0.810 | 9.461 | 0.226 |
miR-1 + cTnI | 0.931 (0.904~0.959) | 0.000 | 86.2 | 90.4 |
0.799
|
0.947
|
3.816
|
0.005
|
The 95% reference range of miR-1
Prognostic value of miR-1 in patients with ACP
Prognostic performance for MACEs (30 days) in patients with ACP | ||||||||
Biomarker | AUC (95%CI) | P value | Sen. | Spe. | PPV | NPV | LR+ | LR- |
miR-1 | 0.620 (0.500~0.740) | 0.046 | 80.0 | 50.3 | 0.113 | 0.970 | 1.610 | 0.397 |
cTnI | 0.469 (0.345~0.594) | 0.612 | 40.0 | 66.5 | 0.086 | 0.933 | 1.192 | 0.903 |
Prognostic performance for overall mortality (720 days) in patients with ACP | ||||||||
Biomarker | AUC (95%CI) | P value | Sen. | Spe. | PPV | NPV | LR+ | LR- |
miR-1 | 0.666 (0.555~0.778) | 0.001 | 47.1 | 86.3 | 0.276 | 0.936 | 3.440 | 0.613 |
cTnI | 0.474 (0.359~0.589) | 0.614 | 20.1 | 88.6 | 0.167 | 0.910 | 1.806 | 0.896 |